Does a higher arachidonic acid-to-EPA balance favor pain-sensitizing inflammation without specifically identifying postherpetic neuralgia?

Postherpetic neuralgia (PHN) follows varicella-zoster reactivation–related injury to sensory ganglia, peripheral nerves, and skin. Its pain phenotype reflects variable combinations of nerve injury, peripheral nociceptor sensitization, and central sensitization; a systemic lipid ratio cannot by itself identify this syndrome.

Biological and pain-mechanism evidence

• A balance favoring arachidonic acid (AA) over EPA plausibly directs cyclooxygenase and lipoxygenase activity toward AA-derived series-2 prostaglandins and series-4 leukotrienes, including PGE₂ and LTB₄. EPA competes for these pathways and gives rise to series-3 prostanoids and series-5 leukotrienes, generally with weaker or distinct inflammatory actions.
• The mechanistic evidence for pain sensitization is strongest for PGE₂: in nerve-injury models, increased PGE₂ in injured nerves and dorsal-root ganglia, acting through peripheral EP receptors, increases sensory-neuron excitability. Persistent COX-2/PGE₂ signaling is linked to chronic neuropathic pain. LTB₄ can also cause hyperalgesia, potentially directly and through recruitment of inflammatory cells.
• This is relevant to PHN because reduced nociceptor thresholds and ectopic spontaneous activity contribute to peripheral sensitization, while sustained peripheral input can promote dorsal-horn hyperexcitability and reduced inhibitory modulation.

Clinical interpretation

• Omega-3 intervention evidence is directionally consistent: a meta-analysis found pooled reductions in serum AA-derived COX prostaglandins and an overall decline in pro-inflammatory eicosanoids in most trials.
• AA/EPA remains an indirect systemic indicator, not a tissue eicosanoid measurement. No study directly connects a measured AA/EPA ratio, a full mediator profile, nociceptor sensitization, and clinical pain in the same population.

Diagnostic implications

• AA/EPA is not a validated diagnostic, predictive, prognostic, or monitoring biomarker for PHN; no PHN-specific threshold, sensitivity, specificity, or ROC/AUC data are established. PHN remains a clinical diagnosis based on persistent dermatomal neuropathic pain after herpes zoster and examination findings such as allodynia or sensory change.

Bottom line

• A higher AA-to-EPA balance is biologically consistent with a more pro-inflammatory, potentially pain-sensitizing mediator environment, particularly through PGE₂, but it neither establishes the cause of an individual’s pain nor specifically identifies PHN.